Corgenix and Randox Laboratories sign collaboration agreement

Under the terms of the agreement, the companies will collaborate in adapting the Corgenix AspirinWorks test to a format compatible with automated chemistry analyzers. The AspirinWorks test will be manufactured at Randox facilities in the UK, and the two companies will share global distribution rights.

AspirinWorks is a simple urine test that determines the effect of aspirin on platelets by measuring the level of thromboxane production. The higher the levels of thromboxane, the stickier the blood platelets, and the less impact the aspirin is having. This crucial information allows physicians to individualize a patient’s aspirin therapy.

Unlike other platelet tests, which require freshly drawn blood that must be evaluated within at least 4 hours, the current AspirinWorks test is said to require only a urine sample that can be obtained in any doctor’s office or patient service center, making the test easy for both physician and patient.

Douglass Simpson, president and CEO of Corgenix, said: “We are very pleased about this new relationship with Randox. They are one of the world’s premier diagnostic companies in automated technology, and together we expect to adapt the important AspirinWorks product into a format suitable for high volume clinical testing.”